Sandbox Reserved 963
From Proteopedia
| Line 1: | Line 1: | ||
<Structure load='3BKM' size='350' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' />{{Sandbox_ESBS}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | <Structure load='3BKM' size='350' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' />{{Sandbox_ESBS}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
==Structure of anti-amyloid-beta Fab W-02 (Form A, P212121)== | ==Structure of anti-amyloid-beta Fab W-02 (Form A, P212121)== | ||
| - | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
'''Alzheimer's disease (AD)''', is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's disease is the difficulty in remembering recently learned information. As the patient with Alzheimer’s disease ages, symptoms such as speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation, can appear. | '''Alzheimer's disease (AD)''', is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's disease is the difficulty in remembering recently learned information. As the patient with Alzheimer’s disease ages, symptoms such as speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation, can appear. | ||
Revision as of 21:55, 29 December 2014
|
| This Sandbox is Reserved from 15/11/2014, through 15/05/2015 for use in the course "Biomolecule" taught by Bruno Kieffer at the Strasbourg University. This reservation includes Sandbox Reserved 951 through Sandbox Reserved 975. |
To get started:
More help: Help:Editing |
Contents |
Structure of anti-amyloid-beta Fab W-02 (Form A, P212121)
Alzheimer's disease (AD), is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's disease is the difficulty in remembering recently learned information. As the patient with Alzheimer’s disease ages, symptoms such as speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation, can appear.
Acetylcholinesterase inhibitors such as rivastigmine, tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.
However, many groups of researchers are seeking a solution to this problem and most of them are currently focused on the activity of a small peptide called Amyloid ß (Aß).
The known cause of this disease is depicted as the presence of the amyloid plaques found in the brains of Alzheimer patients, which are composed of Aß. These are peptides of 36–43 amino acids, obtained via proteolysis of Amyloid Precursor Protein (APP). An immunologic approach to the disease is made. Researchers have developped a monoclonal antibody, W-02 which can bind specifically to the Aß’s epitope, thus leading the complex to be phagocyted.
Biological Function
Disease
Relevance
Structural highlights
This is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
</StructureSection>
